Jignasa Savjani

Dr. Jignasa Savjani


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in European Journal of Pharmacology
Verified
Journal Article
Closed access
JSJignasa Savjani
Jignasa Savjani
SMSuja Mulamkattil
Suja Mulamkattil
BVBhavesh Variya
Bhavesh Variya
SPSnehal Patel
Snehal Patel

1 May 2016 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SSSurmil Shah
Surmil Shah
JSJignasa Savjani
Jignasa Savjani

1 December 2016 in Brazilian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
JSJignasa Savjani
Jignasa Savjani
CPChirag Pathak
Chirag Pathak
Acyclovir is an antiviral drug having potent activity against the virus of herpes family and varicella zoster. Unfortunately, drug suffers very poor oral bioavailability (15-30%). The main objective of present study was to develop acyclovir cocrystals with improved solubility which may result in improvement of bioavailability. Hansen solubility approach was used as a tool to predict the cocrystal formation of a drug with selected coformer. Cocrystals of acyclovir with various coformers were screened in order to enhance their water solubility. Cocrystals of the drug were prepared using various methods like solvent evaporation, wet grinding, and antisolvent addition. Formation of cocrystals by solvent evaporation method was found to be better method amongst all. Optimization of cocrystal formation was carried out by employing different solvents as well as the stoichiometric ratio of acyclovir with that of coformer. Synthesis of cocrystals was optimized using water as a solvent system resulted in good agreements. The potential cocrystal formation of acyclovir was characterized by IR, PXRD and DSC techniques. An in-vitro dissolution study was performed to determine the dissolution rate of cocrystals. The results suggest that acyclovir forms cocrystals with tartaric acid and the initial dissolution rate of synthesized cocrystals were considerably faster as compared to pure acyclovir.

14 February 2022 in Molecules
Verified
Journal Article
Open access
PDF file
JSJignasa Savjani
Jignasa Savjani
BVBhavesh Variya
Bhavesh Variya
SPSnehal Patel
Snehal Patel
SMSuja Mulamkattil
Suja Mulamkattil
HAHarsh S Amin
Harsh S Amin
Harsh S. ShahHarsh S. Shah
Harsh S. Shah
Non-steroidal anti-inflammatory drugs (NSAIDs) are generally utilized for numerous inflammatory ailments. The long-term utilization of NSAIDs prompts adverse reactions such as gastrointestinal ulceration, renal dysfunction and hepatotoxicity; however, selective COX-2 inhibitors prevent these adverse events. Various scientific approaches have been employed to identify safer COX-2 inhibitors, as in any case, a large portion of particular COX-2 inhibitors have been retracted from the market because of severe cardiovascular events. This study aimed to develop and synthesize a novel series of indomethacin analogues with potential anti-inflammatory properties and fewer side effects, wherein carboxylic acid moiety was substituted using DCC/DMAP coupling. This study incorporates the docking of various indomethacin analogues to detect the binding interactions with COX-2 protein (PDB ID: 3NT1). MD simulation was performed to measure the stability and flexibility of ligand–protein interactions at the atomic level, for which the top-scoring ligand–protein complex was selected. These compounds were evaluated in vitro for COX enzymes inhibition. Likewise, selected compounds were screened in vivo for anti-inflammatory potential using the carrageenan-induced rat paw oedema method and their ulcerogenic potential. The acute toxicity of compounds was also predicted using in silico tools. Most of the compounds exhibited the potent inhibition of both COX enzymes; however, 3e and 3c showed the most potent COX-2 inhibition having IC50 0.34 µM and 1.39 µM, respectively. These compounds also demonstrated potent anti-inflammatory potential without ulcerogenic liability. The biological evaluation revealed that the compound substituted with 4-nitrophenyl was most active.

1 March 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HSHarshil R. Shah
Harshil R. Shah
JSJignasa Savjani
Jignasa Savjani

22 November 2021 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
SDSandeep Dahiya
Sandeep Dahiya
KSKetan Savjani
Ketan Savjani
JSJignasa Savjani
Jignasa Savjani